Brief: Orgenesis Enters Into Collaboration Agreement With Mida To Deploy Ompuls For Point-Of-Care Research And Development Of Promising Cell And Gene Therapies
18/03/2021 11:25
March 18 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ENTERS INTO COLLABORATION AGREEMENT WITH MIDA TO
DEPLOY OMPULS FOR POINT-OF-CARE RESEARCH AND DEVELOPMENT OF
PROMISING CELL AND GENE THERAPIES
* ORGENESIS INC - CO, MIDA PLAN TO DEPLOY ORGENESIS MOBILE
PROCESSING UNITS, LABS AT LEADING HOSPITALS
* ORGENESIS - CO, MIDA ENTERED INTO DEAL TO ESTABLISH
POINT-OF-CARE CENTERS, DEPLOY OMPULS WITHIN LEADING HOSPITALS IN
ITALY, GERMANY, SPAIN, BENELUX
Source text for Eikon: ID:nGNX24nhZK
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules